Options Bulls Could Be Right About This Pharma Stock

Fernanda Horner

Wed, April 1, 2026 astatine 12:05 PM CDT 1 min read

Insmed Inc (NASDAQ:INSM) shares were past seen up 0.3% to commercialized astatine $164.03, aft a price-target hike to $237 from $231 astatine Barclays. The pharmaceutical banal is connected way for its third-straight regular summation and conscionable wrapped up its champion period since November, but besides saw its archetypal quarterly nonaccomplishment since 2024. Though the equity carries a 6.2% shortage for 2026, a bullish trendline is present flashing, which whitethorn assistance region the shares from their March underperformance.

The trendline successful question is the stock's 80-day moving average. Per Schaeffer's Senior Quantitative Analyst Rocky White, this “crossover” lawsuit happened 17 different times implicit the past 10 years, aft which the information was higher 1 period aboriginal 59% of the time, averaging a 5.4% gain. From its existent perch, a comparable determination would enactment INSM supra $173 for the archetypal clip since January.

Options traders are overwhelmingly bullish. This is per INSM's 10-day call/put measurement ratio of 64.74 astatine the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) that sits higher than 98% of yearly readings.

Options look similar an charismatic way erstwhile weighing connected the stock's adjacent moves, per its Schaeffer's Volatility Index (SVI) of 43% that sits higher than 12% of readings from the past year. In different words, near-term enactment traders are present pricing successful debased volatility expectations.

Plus, the equity's Schaeffer's Volatility Scorecard (SVS) comes successful astatine an elevated 83 retired of 100. This means the shares person consistently realized higher volatility than the options person priced successful implicit the past 12 months.